Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
out of this flat not worth my time the market is on fire cant lat money just sit here
this swing is going to be a big winner
if you flip it you lose just buy and forget it
got all the shares i need just have to wait now for things to unfold
i posted it in a few other rooms with good traders look for volume
picked up TMTA for a swing today at 1.10
buys DDDC at 1.41 for swing
buying ICGN at .75
icgn trading below cash at .76 cents way to cheap listen to the cc they are working with the fda on the trial where the stock got hit earlier in the year , small float 17m for a bio stock
PRODUCT PIPELINE http://www.icagen.com/about/productpipeline.html
The Company’s four most advanced programs are:
ICA-17043 for sickle cell disease, for which the Company is conducting a Phase III clinical trial;
lead compounds for epilepsy and neuropathic pain, for which the Company is conducting preclinical studies;
a compound for atrial fibrillation, for which the Company’s collaborator Bristol-Myers Squibb Company is conducting preclinical studies; and
lead compounds for dementia, including Alzheimer’s disease, for which the Company’s collaborator Astellas Pharma Inc. is conducting preclinical studies, and lead compounds for attention deficit/hyperactivity disorder, which were derived from the collaboration and for which the Company is conducting preclinical studies.
Icagen is also conducting ongoing drug discovery programs focused on new therapeutics for pain disorders, inflammatory disorders and glaucoma.
AVAN dd
http://www.theage.com.au/news/National/Govt-may-vaccinate-children-against-bug/2006/11/09/1162661823...
Govt may vaccinate children against bug
Email Print Normal font Large font November 9, 2006 - 6:29PM
Advertisement
AdvertisementAll Australian children will be vaccinated against the potentially deadly rotavirus under a plan being considered by the federal government.
The government's drug advisory committee has recommended two vaccines - RotaTeq and Rotarix - be funded as a universal mass vaccination for infants against the common gastro disease.
If approved, all children would be vaccinated in either two or three doses before they are six-months-old.
A health department spokesperson confirmed the Pharmaceutical Benefits Advisory Committee (PBAC) had recommended both vaccines to be included on the Australian National Immunisations Program Schedule in 2007 at a meeting early this month.
This will allow state-based providers to roll-out the program before the next winter seasonal peak for rotavirus, a disease that hospitalises 10,000 Australian children each year.
The move has been applauded by Professor Graeme Barnes, a specialist at the Murdoch Children's Research Institute at the Royal Children's Hospital in Melbourne.
"This is just fantastic, brilliant news, of course on the assumption that the government will act on the recommendation," Prof Barnes said.
"I'm pretty hopeful of that though - and if it does it's going to help so many kids, so that's just great."
buying GTW for a swing 1.76
added some AVAN at 1.39 for a swing trade
insm contract on october 30 has never been pr by insm link to the 7.5 million contract
http://vsearch1.fbo.gov/servlet/SearchServlet
October 30, 2006
Agency: Department of Veterans Affairs
Office: VA National Acquisition Center
Location: Department of Veterans Affairs National Acquisition Center
Posted: October 30, 2006
Type: Award
Title: 65--65 -- 65 I B
Award Number: V797P-5906X (Archived)
http://www.fbo.gov/servlet/Documents/R/1573013
General Information
Document Type: Award Notice
Solicitation Number:
Posted Date: Oct 30, 2006
Archive Date: Oct 30, 2006
Classification Code: 65 -- Medical, dental & veterinary equipment & supplies
SetAsides:
Naics Code: N/A
Contracting Office Address
Attn: Department of Veterans Affairs National Acquisition Center, (049A1), P.O. Box 76, Building No. 37, Hines, Illinois 60141
Description
Contract Award Date: Jun 09, 2006
Contract Award Number: V797P-5906X
Contract Award Amount: $7,500,000
Contract Line Item Number:
Contractor: Insmed Incorporated, 4851 Lake Brook Dr., Glen Allen, Virginia, 23060
good news for INSM
http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B2AFB6779%2DF1AF%2D43E9%2D8CF3%2DF72D28ABD46...
Insmed Provides Update Concerning Virginia Unfair Competition Litigation
PrintE-mailDisable live quotesRSSDigg itDel.icio.usLast Update: 6:42 PM ET Oct 4, 2006
RICHMOND, Va., Oct 04, 2006 /PRNewswire via COMTEX/ -- Insmed Incorporated announced today that the U.S. District Court for the Eastern District of Virginia granted in part Insmed's motion to dismiss unfair competition claims brought against Insmed by Tercica, Inc. In a ruling today, Chief United States District Judge James R. Spencer narrowed the scope of Tercica's lawsuit against Insmed. In dismissing portions of the claims brought by Tercica, the Court found areas in which Tercica had not met its burden of establishing that the alleged statements made by Insmed constituted "false advertising" or violated Virginia law. While the court held that a number of Tercica's other factual allegations, if proven, would state claims for false advertising under federal and California law, in comments at the September 9 hearing, Judge Spencer noted that he felt "most if not all" of Tercica's case "could go out on summary judgment."
About IPLEX
IPLEX is approved in the United States as the only once daily treatment for children with short stature associated with severe primary IGF-I deficiency (Primary IGFD). IPLEX, a complex of recombinant human IGF-I and its binding protein IGFBP-3 (rhIGF-I/rhIGFBP-3), is the only FDA-approved IGF- I replacement therapy that also replaces deficient IGFBP-3 in these patients. The drug, which was launched in the second quarter of 2006, is also being investigated for various other indications with unmet medical needs, including severe insulin resistance, myotonic muscular dystrophy and HIV Associated Adipose Redistribution Syndrome (HARS). For more information about IPLEX please go to http://www.go-IPLEX.com.
About Insmed
buying CMGI for swing at 1.07 also nice pick
buying INHX for a swing,trading below cash small BIO'S being bought
nice news on astm
DJ Aastrom Biosciences Reports Interim Data From Long Bone Non-Union Fracture Clinical Trial>ASTM
09/15/2006
Dow Jones News Services
(Copyright © 2006 Dow Jones & Company, Inc.)
(MORE TO FOLLOW) Dow Jones Newswires
09-15-06 1300ET
Copyright (c) 2006 Dow Jones & Company, Inc.
*DJ Aastrom Biosciences: 10 Of 12 Patients Showed Bone Bridging
very nice news for ICGN
DJ Icagen Reports Results Of Data Monitoring Committee Meeting In Phase III Assert Trial Of ICA-17043>ICGN
09/12/2006
Dow Jones News Services
(Copyright © 2006 Dow Jones & Company, Inc.)
(MORE TO FOLLOW) Dow Jones Newswires
09-12-06 0730ET
Copyright (c) 2006 Dow Jones & Company, Inc.
*DJ Icagen: Committee Recommends Assert Trial Continue Enrollment
(MORE TO FOLLOW) Dow Jones Newswires
09-12-06 0734ET
Copyright (c) 2006 Dow Jones & Company, Inc.
DJ Icagen Cmte Urges Combination Therapy In Sickle-Cell Trial
DOW JONES NEWSWIRES
Icagen Inc. (ICGN) said its independent data-monitoring committee recommended continuing to enroll patients on a combination therapy in the company's Phase III clinical trial of an oral sickle-cell disease treatment.
The Durham, N.C., biopharmaceutical company said the data committee recommended continuing to enroll patients on hydroxyurea therapy in its clinical trial of ICA-17043 to treat the genetic blood disorder.
Icagen said combination therapy might prove more effective at treating the disease than a single treatment alone; the company said it would discuss the committee's recommendation with the U.S. Food and Drug Administration.
in astm for meeting on the 15th
American Society for Bone & Mineral Research
~ 28th Annual Meeting ~
Aastrom Biosciences, Inc.
will present an oral presentation at the meeting
http://www.aastrom.com/AastromEvents.asp?GetLink=http%3A%2F%2Fwww%2E7ware%2Ecom%2FEvent%2FCOE%5FView...
in ICGN AT 1 HAS 1.6 in cash with small float small bio,s are moving
17m float has 1.6 in cash way to cheap
great calls on ASTM and MEMY
back in GENR for swing at .56 will move back up soon
Genaera Completes $25.1 Million Financing
Friday June 30, 4:30 pm ET
PLYMOUTH MEETING, Pa., June 30 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) announced today that it has closed its previously disclosed registered direct offering. The Company sold 35,589,972 shares of its common stock and warrants to purchase 26,692,477 million shares of its common stock at a purchase price of $0.70385 per unit for aggregate gross proceeds of $25.1 million. The warrants have an exercise price of $0.6101. Banc of America Securities LLC acted as lead placement agent and Fortis Securities LLC acted as co-placement agent for the offering.
ADVERTISEMENT
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission. A prospectus and prospectus supplement relating to this transaction may be obtained directly from the Company or from the U.S. Securities and Exchange Commission at http://www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, and these securities cannot be sold in any state in which this offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
nice news on genr
Genaera Receives Patent for Gene Variants of Interleukin-9 Receptor
PR Newswire - June 23, 2006 08:30
PLYMOUTH MEETING, Pa., June 23, 2006 /PRNewswire-FirstCall via COMTEX/ -- Genaera Corporation (Nasdaq: GENR) today announced issuance by the United States Patent and Trademark Office of patent number 7,056,698 entitled "Nucleic Acids Encoding Interleukin-9 Receptor Variants." The patent relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Interleukin-9 (IL-9) receptor. Patent expiry occurs in November 2018.
"The protection provided by this patent further strengthens our intellectual property position around the naturally occurring variants of the IL-9 receptor," said Jack Armstrong, President and Chief Executive Officer. "This receptor is central to the development of diagnostic methods, research tools, and most importantly, new therapies for atopic asthma, allergy and other IL-9 related diseases. We are delighted to have secured additional value for our research efforts in allergy and respiratory diseases."
About IL-9
IL-9 has been associated with symptoms of asthma including mucous production, lung infiltration of inflammatory cells, and IgE (an immune globulin associated with allergic disease) production. It is one of at least 29 naturally occurring interleukins in the human body. Under the April 2001 collaboration and license agreement between Genaera and MedImmune, Inc., U.S. Patent Number 7,056,698 is exclusively licensed to MedImmune for the development of an IL-9 product for the treatment or prevention of asthma and other diseases and/or disorders. Genaera retains the rights to diagnostics and vaccines.
About Genaera
Genaera Corporation is a biopharmaceutical company committed to developing medicines to address substantial unmet medical needs in major pharmaceutical markets. The Company has products in development for the treatment of eye, cancer, respiratory disorders and metabolic syndrome. EVIZON(TM) (squalamine lactate) is Genaera's lead product in development for ophthalmic indications, specifically wet age-related macular degeneration (AMD). Genaera's other programs include: squalamine for the treatment of cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease; and trodusquemine (MSI-1436) for the treatment of obesity.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding preliminary results, future clinical development plans and prospects for Genaera's programs, including EVIZON(TM) (squalamine lactate), squalamine, LOMUCIN(TM), IL-9 antibody and trodusquemine (MSI-1436). You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "develop," "expect," "continue," and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to; Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including EVIZON(TM), squalamine, LOMUCIN(TM), IL-9 antibody and trodusquemine (MSI-1436) may be delayed or not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.
SOURCE Genaera Corporation
Genaera Corporation Investor Relations, +1-610-941-5676; or Celeste Duncan, The Trout
Group (Investor Inquiries), +1-212-477-9007; or Mike Beyer, Sam Brown, Inc. (Media
Inquiries), +1-773-463-4211, beyer@sambrown.com
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved. ********************************************************************** As of Monday, 06-19-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 02-24-2006 for GENR @ $1.73. (C) 2006 Comtex News Network, Inc. All rights reserved.
--------------------------------------------------------------------------------
picked up some GENR at .70 for a swing might have news on the 27-28th from pr its oversold anyway
Genaera Corporation to Present at IBC Ocular Anti-Angiogenesis Conference
Thursday June 22, 8:30 am ET
PLYMOUTH MEETING, Pa., June 22 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) will present at the First IBC European Ocular Anti-angiogenesis Conference being held June 27-28, 2006 at the Cafe Royale in London, UK. Michael J. Gast, M.D., Ph.D., Senior Vice President, Clinical Research and Development, will present on Tuesday, June 27, 2006 at 5:30 PM GMT.
ADVERTISEMENT
The presentation will highlight recent findings from the Company's Phase II clinical trials with EVIZON(TM) (squalamine lactate) for the treatment of wet age-related macular degeneration (AMD). Squalamine lactate is a first-in- class, anti-angiogenic small molecule being developed for exudative AMD and oncology.
Genaera Corporation is a biopharmaceutical company committed to developing medicines to address substantial unmet medical needs in major pharmaceutical markets. The Company has products in development for the treatment of eye, cancer, respiratory disorders and metabolic syndrome. EVIZON(TM) (squalamine lactate) is Genaera's lead product in development for ophthalmic indications, specifically wet age-related macular degeneration (AMD). Genaera's other programs include: squalamine for the treatment of cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease; and trodusquemine (MSI-1436) for the treatment of obesity
thanks
buying INSM at 1.46 for swing for the endo conference on june 27
BIGGEST JUNE EVENT WILL BE THE FORMAL RELEASE OF PHASE 2 SEVERE INSULIN RESISTANCE CLINICAL DATA (IPLEX)AT THE ENDO CONFERENCE ON JUNE 27
1) IPlex Commercial Launch in MAY----- 4 weeks ahead of schedule!!
2) INSM will formally apply with the EMEA in a few weeks for iPLex approval in Europe. iPLex has already been approved in Europe for Severe Insulin Resistance. INSM has not ruled out a partnership with a large pharma Co. to market iPlex in Europe.
3) Earnings for 2Q will exceed analysts' expectation by a wide margin because of 1 above.
4) Surveys by analysts indicate that IPlex is preferred by pediatric doctors for safety reasons and once/daily dosage.
5) INSM has $60M in cash. Enough to fund operations until mid-2007.
6) INSM will present "COMPELLING DATA" for phase 2 clinical results using iPlex to decrease Severe Insulin Resistance. Presentation will be made in 3 weeks at the ENDO international Show/Conference. Expect more than 10M shares traded that day.
6)ASCO published this week a milestone paper describing the relationship between PB3 and cancer prevention/cure. Eseentially PB3 neutralizes excess IGF-1 (Increlex) which if allowed to exist unbuffered could fuel uncontrolled cell growth including tumors/cancer.
Reminder....iPlex is a combination of iGF-1 and PB3. IPlex uses BP3 to regulate IGF-1 distribution in the body, thus avoiding unbuffered IGF-1. FYI, INSM is conducting cancer trials using BP3.
http://www.asco.org/portal/site/ASCO/menuitem.d773f70619f767fd506fe310ee37a01d/? vgnextoid=4cca201eb61a7010VgnVCM100000ed730ad1RCRD&reuterview=detail_view&reuter sid=4868
ABOUT IPLEX. iPlex is a proprietary INSM drug product for the delivery of recombinant insulin-like growth factor 1 (IGF-1). It is administered as a preformed complex with a recombinant form of its natural binding protein, insulin-like growth factor binding protein 3 (rhIGFBP-3). iPLEX is administered as a once-daily subcutaneous injection, which can restore and maintain IGF-1 levels to physiologically relevant levels.
OTHER ONGOING CLINICAL DEVELOPMENT:
* NOONAN's syndrome trials. This is to expand iPlex patient base from 6,000 to over 30,000.
* Miotonic Muscular Disthrophy (MMD) clinical trials using iPlex are well under way. The University of Rochester School of Medicine, and the Muscular Dystrophy Association (MDA) announced in March 2006 the initiation of a Phase 2 clinical study investigating the use of iPlex(TM) for the treatment of MMD.
Myotonic dystrophy affects an estimated 40,000 individuals in the United States and causes progressive muscle wasting and weakness in the hands, forearms, legs, neck and face.
* BP3 cancer trials....Ongoing (see ASCO news above)
The company's product candidate (BP3), rhIGFBP-3, recombinant human Insulin-like Growth Factor Binding Protein-3, is a naturally occurring anti-tumor agent. rhIGFBP-3 has demonstrated preclinical efficacy in numerous cancer indications, including breast, prostate, liver, ovarian, and colon cancers.
Recent independent studies have demonstrated rhIGFBP-3 used in combination can accentuate and even synergize the efficacy of standard cancer therapies.
* INSM-18 AT THE FOREFRONT OF NEW CANCER DRUGS....EVEN AHEAD OF PFYZER IN THIS AREA
On March 7, 2006, the Business Intelligence firm La Merie S.L. reported that antibodies are at the forefront of novel cancer therapeutics targeting the insulin-like growth factor-1 receptor (IGF-1R).
The report states that INSM along with giant Pfizer are among the leaders in this promising oncology research area. INSM-18 is a dual inhibitor of IGF-1R and Her2/neu and is the only clinical stage IGF-1R small molecule antagonist (phase I/II in pr
back in AAC for a swing at .35
Ableauctions Reports First Quarter 2006 Financial Results
Monday May 15, 10:30 am ET
OJAI, Calif.--(BUSINESS WIRE)--May 15, 2006--Ableauctions.com Inc. (AMEX:AAC - News) today announced the results of operations for the quarter ended March 31, 2006.
The Company reported revenue of $2,039,152 for the quarter ended March 31, 2006, compared to revenue of $1,149,744 during the same period in 2005, an increase of 77%. The Company reported net income of $140,310 for the quarter ended March 31, 2006, compared to a loss of $169,563 during the same period in 2005.
The increase in revenues was attributed to stronger performance in the Company's auction broadcast services, iCollector.com and NAALive.com, and the business sector related to the liquidation of surplus inventory, which is managed through its subsidiary Unlimited Closeouts, Inc.
Gross profits from revenue was $709,386, or 35% of revenues for the three-months ended March 31, 2006 as compared to $272,428, or 24% of revenues, for the three months ended March 31, 2005. The increase in gross profit as a percentage of revenue is attributed to the performance of the Company's online auction business, which realizes higher gross profit margins, and on its ability to realize higher margins from its liquidation services.
The Company reported shareholders' equity, defined as the value of the Company's assets minus its liabilities, of $12,870,708 at March 31, 2006 compared to $12,789,331 at December 31, 2005.
The Company's objective is to become a leading provider of liquidation and merchandising services. Management believes that the Company's long term success in this area of our business depends on its continued innovation and integration of technologies and services for auctioneers and liquidators worldwide.
About Ableauctions.com
gtcb boom
DJ ATryn(R) Gets CHMP Recommendation To Grant Market Authorization; Indicated For Prophylactic Treatment Of Hereditary Antithrombin Deficient Patients Undergoing Surgery>GTCB
06/02/2006
Dow Jones News Services
(Copyright © 2006 Dow Jones & Company, Inc.)
(MORE TO FOLLOW) Dow Jones Newswires
06-02-06 0712ET
Copyright (c) 2006 Dow Jones & Company, Inc.
DJ GTC Biotherap's ATryn Gets Recommended For European OK
DOW JONES NEWSWIRES
GTC Biotherapeutics Inc.'s (GTCB) treatment for hereditary antithrombin-deficient patients undergoing surgery received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.
GTC said Friday the committee recommended market authorization for ATryn, which may be given in association with heparin or low molecular weight heparin.
The Framingham, Mass., company expects final market authorization by the European Commission in about three months.
The biomedical concern also said ATryn is in a Phase III study of the hereditary deficiency indication as the company prepares a Biologics License Application with the Food and Drug Administration.
-Eamon Beltran; 201-938-5400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
06-02-06 0740ET
Copyright (c) 2006 Dow Jones & Company, Inc.
AXYX presenting on may 16
NEW YORK, May 09, 2006 (BUSINESS WIRE) -- Axonyx Inc. (NASDAQ: AXYX) today announced that Gosse B. Bruinsma, MD, President and CEO of Axonyx, will be presenting at the Rodman and Renshaw 3rd Annual Global Healthcare Conference in Monte Carlo, Monaco on Tuesday, May 16 at 9:25 AM local time (3:25 AM EDT). Dr. Bruinsma is expected to discuss the Company's clinical development program, strategic initiatives and market opportunities. Parties interested in scheduling 1-on-1 meetings with Dr. Bruinsma are invited to contact Lily Khaykina at LK@rodmanandrenshaw.com.
back in GENR at 1.27 swing for april 26 presentation
Genaera Corporation to Present at 6th Annual Fortis Bank Biotechnology Conference
Monday April 24, 9:00 am ET
PLYMOUTH MEETING, Pa., April 24 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) will present at the 6th Annual Fortis Bank Biotechnology Conference being held April 26, 2006 at the Four Seasons Hotel, Park Lane, London, UK. Jack Armstrong, President and Chief Executive Officer, will present at 9:00 AM GMT.
ADVERTISEMENT
The presentation will be an overview of the Company's development programs and will highlight recent findings, including fellow eye data, from the Company's Phase II clinical trials with EVIZON(TM) (squalamine lactate) for the treatment of wet age-related macular degeneration (AMD). In addition, the Company will present recent findings related to its anti-obesity compound, MSI-1436.
Genaera Corporation is a biopharmaceutical company committed to developing medicines to address substantial unmet medical needs in major pharmaceutical markets. The Company has four products in development for the treatment of eye, cancer and respiratory disorders. EVIZON(TM) (squalamine lactate) is Genaera's lead product in development for ophthalmic indications, specifically wet age-related macular degeneration (AMD). Genaera's other programs include: squalamine for the treatment of cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease.
in GTCB at 1.01 for swing should see news by june this stock has a history of large swings before the news
here is a link to the cc a good listen
http://phx.corporate-ir.net/phoenix.zhtml?c=114239&dc=&p=irol-Guestbook&UniqueId=1215528...
GTC has exercised its right to have its application re-examined, and expects the re-examination to conclude in mid-2006. However, in a public statement by a spokesperson for the EMEA who was quoted in a February 24 article published in Nature.com, the negative opinion was not related to the source of the product being from a transgenic animal.
In November 2005, GTC and LEO Pharma entered into a collaboration to develop and market ATryn® in Europe, Canada, and the Middle East. LEO is responsible for clinical development of ATryn® in an acquired antithrombin deficiency indication in Europe. GTC is responsible for ATryn® production and will receive a transfer payment from LEO for all product used in the acquired deficiency clinical study and a royalty on future commercial sales. The acquired deficiency indication to be studied is expected to be selected by mid-2006.
in AXYX at 1.05 for swing
presentations of data on Axonyx’s drug development candidates, Phenserine and Posiphen™, will be made at the 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy in Geneva, Switzerland, being held April 19-22, 2006.
the news is at the bottom of the home page
http://www.axonyx.com/
shorting the qqqq at 42.49 for a swing
GENR NICE
DJ Genaera Corp Presents Encouraging Data On Bilateral Visual Acuity In Subjects From EVIZON Phase II Trials>GENR
03/29/2006
Dow Jones News Services
(Copyright © 2006 Dow Jones & Company, Inc.)
(MORE TO FOLLOW) Dow Jones Newswires
03-29-06 1517ET
Copyright (c) 2006 Dow Jones & Company, Inc.
*DJ Genaera:Data Suggest Evizon Stabilizes Or Improves Vision
(MORE TO FOLLOW) Dow Jones Newswires
03-29-06 1518ET
Copyright (c) 2006 Dow Jones & Company, Inc.
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
in some AXYX at 1.11 for swing 1.08 in cash 0 debt
As of December 31, 2005, the Company had $58,338,000 in cash, cash equivalents and investments and $53,293,000 in working capital.
GENR is a few at 1.29
Genaera Corporation to Present at IBC Ocular Anti-angiogenesis Conference
Monday March 27, 8:00 am ET
PLYMOUTH MEETING, Pa., March 27 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) will present at the IBC Third Annual Ocular Anti- angiogenesis Conference being held March 29-30, 2006 at the Hotel @ MIT in Cambridge, MA. Michael J. Gast, M.D., Ph.D., Senior Vice President, Clinical Research and Development, will present on Wednesday, March 29, 2006 at 3:00 PM.
ADVERTISEMENT
The presentation will highlight recent findings from the Company's Phase II clinical trials with EVIZON(TM) (squalamine lactate) for the treatment of wet age-related macular degeneration (AMD). Squalamine lactate is a first-in- class, anti-angiogenic small molecule being developed for exudative AMD and oncology.
Genaera Corporation is a biopharmaceutical company committed to developing medicines to address substantial unmet medical needs in major pharmaceutical markets. The Company has four products in development for the treatment of eye, cancer and respiratory disorders. EVIZON(TM) (squalamine lactate) is Genaera's lead product in development for ophthalmic indications, specifically wet age-related macular degeneration (AMD). Genaera's other programs include: squalamine for the treatment of cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease.
in WGAT for swing at 1.41
WGAT low float low on chart 21m cash 0 debt
WorldGate Communications, Inc. engages in the development, manufacture, and distribution of video phones for personal and business use. The company primarily offers Ojo video phone, which is useful for video calls, ordinary voice only calls, as well as voice over Internet protocol calls. Its Ojo solution consists of a display unit that includes a camera, video screen, and external interface ports, as well as a cordless handset with an internal speaker and microphone. WorldGate markets and distributes products through its distribution partner, Motorola, Inc., to residential and business sectors worldwide. The company was founded by Hal M. Krisbergh in 1995 and is headquartered in Trevose, Pennsylvania.
watch CNXT moving with mspd
cnxt holds warrant to purchase 30 million shares of mspd
We hold a warrant to purchase 30 million shares of common stock of Mindspeed. For financial accounting purposes, this is a derivative instrument and the fair value of the warrant is subject to significant risk related to changes in the market price of Mindspeed’s common stock. As of December 31, 2005, a 10% decrease in the market price of Mindspeed’s common stock would decrease the fair value of this warrant by approximately $4.1 million. At December 31, 2005, the market price of Mindspeed’s common stock was $2.35 per share. For the quarter ended December 31, 2005, the market price of Mindspeed’s common stock ranged from a low of $1.68 per share to a high of $2.47 per share
more insider buying on 3/10/2006 GENR
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0000880431%2D06%2D000009%2Etxt&FilePath...
insiders starting to buy into GENR on 3/8/2006
http://www.nasdaq.com/asp/quotes_sec.asp?mode=&kind=&timeframe=&intraday=&charttype=...
bought into AAC for swing today at .34